Curevo Vaccine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Curevo Vaccine, a privately held clinical-stage biotechnology company focused on developing safe and effective vaccines to reduce the burden of infectious diseases, has announced its selection to present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation, led by CEO George Simeon, will cover updated data from Curevo's 876-patient head-to-head trial of amezosvatein, a non-mRNA adjuvanted subunit vaccine for shingles, compared to Shingrix®.

The presentation is scheduled for Wednesday, January 15th, at 5:00pm Pacific Standard Time in the Golden Gate room on the 32nd floor. Curevo's lead product, amezosvatein, aims to address the current challenges in the shingles vaccine market, including accessibility issues and vaccine hesitancy due to tolerability concerns. The company is also developing a non-live, non-mRNA adjuvanted subunit chickenpox vaccine to improve immunization rates among immunocompromised children.

Shingrix® is a registered trademark of GlaxoSmithKline, PLC.